Free Trial
NASDAQ:ZBIO

Zenas BioPharma Q2 2025 Earnings Report

Zenas BioPharma logo
$16.82 +0.06 (+0.36%)
As of 08/15/2025 04:00 PM Eastern

Zenas BioPharma EPS Results

Actual EPS
-$1.25
Consensus EPS
-$1.02
Beat/Miss
Missed by -$0.23
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zenas BioPharma's Q3 2025 earnings is scheduled for Thursday, August 21, 2025

Zenas BioPharma Earnings Headlines

Zenas BioPharma Q3 EPS Forecast Decreased by HC Wainwright
New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.
Zenas BioPharma Reports Q2 2025 Financial Results
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

View Zenas BioPharma Profile

More Earnings Resources from MarketBeat